John Varian - Net Worth and Insider Trading

John Varian Net Worth

The estimated net worth of John Varian is at least $188,893 dollars as of 2024-11-13. John Varian is the Director of XOMA Royalty Corp and owns about 5,995 shares of XOMA Royalty Corp (XOMA) stock worth over $188,843. John Varian is also the Director of Aravive Inc and owns about 1,267 shares of Aravive Inc (ARAV) stock worth over $51. Details can be seen in John Varian's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Varian has not made any transactions after 2017-05-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of John Varian

John Varian Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Varian owns 7 companies in total, including SELLAS Life Sciences Group Inc (SLS) , Egalet Corp (EGLTQ) , and Aravive Inc (ARAV) among others .

Click here to see the complete history of John Varian’s form 4 insider trades.

Insider Ownership Summary of John Varian

Ticker	Comapny	Transaction Date	Type of Owner
SLS	SELLAS Life Sciences Group Inc	2019-03-14	director
EGLTQ	Egalet Corp	2019-01-31	director
ARAV	Aravive Inc	2016-08-25	director
		2017-05-16	director & Director and CEO
		2010-02-25	COO & CFO
		2013-07-15	director & Director and CEO
		2022-01-01	director

John Varian Latest Holdings Summary

John Varian currently owns a total of 2 stocks. Among these stocks, John Varian owns 5,995 shares of XOMA Royalty Corp (XOMA) as of May 16, 2017, with a value of $188,843 and a weighting of 99.97%. John Varian also owns 1,267 shares of Aravive Inc (ARAV) as of August 25, 2016, with a value of $51 and a weighting of 0.03%.

Latest Holdings of John Varian

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XOMA	XOMA Royalty Corp	2017-05-16	5,995	31.50	188,843
ARAV	Aravive Inc	2016-08-25	1,267	0.04	51

Holding Weightings of John Varian

John Varian Form 4 Trading Tracker

According to the SEC Form 4 filings, John Varian has made a total of 0 transactions in XOMA Royalty Corp (XOMA) over the past 5 years. The most-recent trade in XOMA Royalty Corp is the sale of 39,540 shares on May 16, 2017, which brought John Varian around $246,730.

According to the SEC Form 4 filings, John Varian has made a total of 0 transactions in Aravive Inc (ARAV) over the past 5 years. The most-recent trade in Aravive Inc is the sale of 267 shares on August 25, 2016, which brought John Varian around $20,752.

Insider Trading History of John Varian

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John Varian Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

John Varian Ownership Network

Ownership Network List of John Varian

No Data

Ownership Network Relation of John Varian

John Varian Owned Company Details

What does SELLAS Life Sciences Group Inc do?

Who are the key executives at SELLAS Life Sciences Group Inc?

John Varian is the director of SELLAS Life Sciences Group Inc. Other key executives at SELLAS Life Sciences Group Inc include EVP & Gen. Counsel & Corp. Sec. Barbara A Wood , VP & Finance & Corp Controller John Thomas Burns , and director & President and CEO Angelos M. Stergiou .

SELLAS Life Sciences Group Inc (SLS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of SELLAS Life Sciences Group Inc (SLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of SELLAS Life Sciences Group Inc (SLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

SELLAS Life Sciences Group Inc (SLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

SELLAS Life Sciences Group Inc Insider Transactions

No Available Data

What does Egalet Corp do?

Who are the key executives at Egalet Corp?

John Varian is the director of Egalet Corp. Other key executives at Egalet Corp include 10 percent owner Loan Security Holdings I Llc , director & President and CEO Todd N Smith , and Chief Operating Officer Mark Strobeck .

Egalet Corp (EGLTQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Egalet Corp (EGLTQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Egalet Corp (EGLTQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Egalet Corp (EGLTQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Egalet Corp Insider Transactions

No Available Data

What does Aravive Inc do?

Who are the key executives at Aravive Inc?

John Varian is the director of Aravive Inc. Other key executives at Aravive Inc include Chief Commercial Officer Maria Carolina Petrini , Chief Medical Officer Robert B. Geller , and Chief Financial Officer Rudy Howard .

Aravive Inc (ARAV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aravive Inc (ARAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aravive Inc (ARAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aravive Inc (ARAV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aravive Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

John Varian is the director & Director and CEO of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , director & Interim CEO Owen Hughes , and other: See Explanation of Responses Biotechnology Value Fund L P .

XOMA Royalty Corp (XOMA) Insider Trades Summary

Over the past 18 months, John Varian made no insider transaction in XOMA Royalty Corp (XOMA). Other recent insider transactions involving XOMA Royalty Corp (XOMA) include a net purchase of 9,100 shares made by Bradley Sitko , and a net purchase of 5,500 shares made by Owen Hughes .

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMA) were sold and 14,600 shares were bought by its insiders, resulting in a net purchase of 14,600 shares.

XOMA Royalty Corp (XOMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does ARYx Therapeutics Inc do?

Who are the key executives at ARYx Therapeutics Inc?

John Varian is the COO & CFO of ARYx Therapeutics Inc. Other key executives at ARYx Therapeutics Inc include 10 percent owner Growth Equity Opportunities Fund, Llc , 10 percent owner Krishna Kittu Kolluri , and 10 percent owner Mark W Perry .

ARYx Therapeutics Inc (ARYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ARYx Therapeutics Inc (ARYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYx Therapeutics Inc (ARYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ARYx Therapeutics Inc (ARYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARYx Therapeutics Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

XOMA Royalty Corp (XOMAO.PFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMAO.PFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMAO.PFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

XOMA Royalty Corp (XOMAO.PFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does Acorda Therapeutics Inc do?

Who are the key executives at Acorda Therapeutics Inc?

John Varian is the director of Acorda Therapeutics Inc. Other key executives at Acorda Therapeutics Inc include CEO and President Ron Cohen , Chief Financial Officer Michael A Gesser , and General Counsel Neil S. Belloff .

Acorda Therapeutics Inc (ACORQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Acorda Therapeutics Inc (ACORQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acorda Therapeutics Inc (ACORQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Acorda Therapeutics Inc (ACORQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acorda Therapeutics Inc Insider Transactions

No Available Data

John Varian Mailing Address

Above is the net worth, insider trading, and ownership report for John Varian. You might contact John Varian via mailing address: Aryx Therapeutics,inc., 6300 Dumbarton Circle, Fremont Ca 94555.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.